Small-molecule drug shows potential for hard to treat cancers
Experts from the University of of Dundee’s Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim scientists, have developed a breakthrough small-molecule drug, a “protein degrader.”